{
  "id": 19578214,
  "title": "Trevi Therapeutics director Michael Heffernan sells $595,805 in stock",
  "url": "https://urgent.news/2026/11/12/trevi-therapeutics-director-michael-heffernan-sells-595-805-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-12T00:31:42.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/trevi-therapeutics-director-michael-heffernan-sells-595805-in-stock-93CH-5020118"
  },
  "original_language": "en",
  "account": "Michael Heffernan, a Trevi Therapeutics, Inc. (NASDAQ:TRVI) director, executed a significant transaction on September 15, 2026. He sold 39,473 shares of common stock, amounting to $595,805, through a Rule 10b5-1 trading plan that was approved on June 16, 2026. The stock was sold at a range of prices, from $15.09 to $15.88. In parallel, Heffernan exercised 39,473 stock options, valued at $126,103, with prices ranging from $3.04 to $3.33. The company's shares had seen a 15.65% increase over the previous week, trading at $14.81 with a market capitalization of $2.13 billion. Despite the insider sale, Trevi Therapeutics remains a focus for investors, given its advancements in the chronic cough pipeline and its robust financial position.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}